All In Biotech

Drug Trial Radar · NCT00654901

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants

Last checked: Nov 20, 2026Latest source record: May 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 881 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

881

Actual

Start

Mar 2008

Primary completion

May 2009

Study completion Jul 2009

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 9, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 15 months, up to 18 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity * To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP\~T or Infanrix hexa™. * To describe the immunogenicity of a booster dose of DTaP-IPV-HepB-PRP\~T in a subset of subjects. Safety \- To describe the safety profile after a booster dose of DTacP-IPV-HepB-PRP\~T.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis
  • Hepatitis B
  • Poliomyelitis
  • Haemophilus Influenzae Type B Infection

Interventions

  • DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)Biological

    0.5 mL, Intramuscular

  • DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)Biological

    0.5 mL, Intramuscular

  • DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)Biological

    0.5 mL, Intramuscular

  • Infanrix Hexa™Biological

    0.5 mL, Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~TTime frame: Day 0 (pre-booster) and Day 30 (one month post-booster)
  2. Number of Participants With Antibody Persistence Before and Immunogenicity Response After Booster Vaccination With DTaP-IPV-Hep B-PRP~T VaccineTime frame: Day 0 (pre-booster) and Day 30 (one month post-booster)
  3. Number of Participants With Solicited Injection Site or Systemic Reactions After Vaccination With DTaP-IPV-Hep B-PRP~T VaccineTime frame: Days 0 up to 7 after any injection

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Estado de México, Mexico

  • Site not named

    Insurgentes Cuicuilco, Mexico

  • Site not named

    Monterrey, Mexico

  • Site not named

    Puebla City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.